Stephen Caldwell

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi request reprint Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management
    Stephen H Caldwell
    University of Virginia, Digestive Health Center of Excellence, GI Hepatology Division, Charlottesville, VA 22908 0705, USA
    Hepatology 44:1039-46. 2006
  2. doi request reprint Gastric varices: is there a role for endoscopic cyanoacrylates, or are we entering the BRTO era?
    Stephen Caldwell
    Division of Gastroenterology and Hepatology, University of Virginia Medical Center, Charlottesville, Virginia 22908 0708, USA
    Am J Gastroenterol 107:1784-90. 2012
  3. ncbi request reprint Treating NAFLD: future prospects
    Stephen H Caldwell
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    J Clin Gastroenterol 40:S67-8. 2006
  4. ncbi request reprint Enbucrilate for gastric varices: extended experience in 92 patients
    S H Caldwell
    GI Hepatology Division, Digestive Health Center of Excellence, University of Virginia Medical Center, Charlottesville, VA 22908 0708, USA
    Aliment Pharmacol Ther 26:49-59. 2007
  5. ncbi request reprint Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
    Stephen H Caldwell
    Division of GI Hepatology, Digestive Health Center of Excellence, University of Virginia, Charlottesville, Virginia 22908 0708, USA
    J Gastroenterol Hepatol 22:S11-9. 2007
  6. ncbi request reprint The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis
    Stephen H Caldwell
    Gastrointestinal Hepatology Division, Digestive Health Center of Excellence, University of Virginia, Charlottesville, VA 22908, USA
    Hepatology 46:1101-7. 2007
  7. doi request reprint Coagulation disorders and bleeding in liver disease: future directions
    Stephen H Caldwell
    GI Hepatology Division, Digestive Health Center of Excellence, University of Virginia Medical Center, Box 800708, Charlottesville, VA 22908 0708, USA
    Clin Liver Dis 13:155-7. 2009
  8. doi request reprint Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis
    Stephen H Caldwell
    Division of GI Hepatology, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908 0708, USA
    Hepatology 49:1888-95. 2009
  9. ncbi request reprint Is exercise an effective treatment for NASH? Knowns and unknowns
    Stephen Caldwell
    The University of Virginia, Division of GI Hepatology, Charlottesville, Virginia, Charlottesville, VA 22908 0708, USA
    Ann Hepatol 8:S60-6. 2009
  10. pmc Hepatocellular ballooning in NASH
    Stephen Caldwell
    GI Hepatology, University of Virginia, Charlottesville, VA, USA
    J Hepatol 53:719-23. 2010

Research Grants

  1. Omega-3 Fish Oil for Nonalcoholic Steatohepatitis
    Stephen Caldwell; Fiscal Year: 2007

Collaborators

Detail Information

Publications49

  1. ncbi request reprint Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management
    Stephen H Caldwell
    University of Virginia, Digestive Health Center of Excellence, GI Hepatology Division, Charlottesville, VA 22908 0705, USA
    Hepatology 44:1039-46. 2006
    ....
  2. doi request reprint Gastric varices: is there a role for endoscopic cyanoacrylates, or are we entering the BRTO era?
    Stephen Caldwell
    Division of Gastroenterology and Hepatology, University of Virginia Medical Center, Charlottesville, Virginia 22908 0708, USA
    Am J Gastroenterol 107:1784-90. 2012
    ..Here, I provide a perspective based on existing literature, 15 years of experience with various cyanoacrylates, and 4 years of experience with BRTO...
  3. ncbi request reprint Treating NAFLD: future prospects
    Stephen H Caldwell
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    J Clin Gastroenterol 40:S67-8. 2006
  4. ncbi request reprint Enbucrilate for gastric varices: extended experience in 92 patients
    S H Caldwell
    GI Hepatology Division, Digestive Health Center of Excellence, University of Virginia Medical Center, Charlottesville, VA 22908 0708, USA
    Aliment Pharmacol Ther 26:49-59. 2007
    ..We assessed N-2-butyl-cyanoacrylate (enbucrilate) in 92 patients with gastric variceal bleeding under an FDA-approved investigation. These results extend our prior report of the first 44 patients...
  5. ncbi request reprint Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
    Stephen H Caldwell
    Division of GI Hepatology, Digestive Health Center of Excellence, University of Virginia, Charlottesville, Virginia 22908 0708, USA
    J Gastroenterol Hepatol 22:S11-9. 2007
    ....
  6. ncbi request reprint The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis
    Stephen H Caldwell
    Gastrointestinal Hepatology Division, Digestive Health Center of Excellence, University of Virginia, Charlottesville, VA 22908, USA
    Hepatology 46:1101-7. 2007
    ..Macrosteatosis (P < 0.001) and Mallory bodies (P = 0.05) significantly decreased, but no change was evident in microsteatosis, cellular enlargement, dilated endoplasmic reticulum, or apoptosis...
  7. doi request reprint Coagulation disorders and bleeding in liver disease: future directions
    Stephen H Caldwell
    GI Hepatology Division, Digestive Health Center of Excellence, University of Virginia Medical Center, Box 800708, Charlottesville, VA 22908 0708, USA
    Clin Liver Dis 13:155-7. 2009
    ..The challenge lies ahead...
  8. doi request reprint Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis
    Stephen H Caldwell
    Division of GI Hepatology, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908 0708, USA
    Hepatology 49:1888-95. 2009
    ..Randomization testing (Monte Carlo resampling) confirmed that the detection of IMCs was strongly dependent on fixation temperature (P < 0.0001)...
  9. ncbi request reprint Is exercise an effective treatment for NASH? Knowns and unknowns
    Stephen Caldwell
    The University of Virginia, Division of GI Hepatology, Charlottesville, Virginia, Charlottesville, VA 22908 0708, USA
    Ann Hepatol 8:S60-6. 2009
    ....
  10. pmc Hepatocellular ballooning in NASH
    Stephen Caldwell
    GI Hepatology, University of Virginia, Charlottesville, VA, USA
    J Hepatol 53:719-23. 2010
    ..Fat droplets are emerging as important organelles in cell metabolism. To address a possible relation between fat droplets and ballooning, we studied fat staining, H&E, and keratin 18 staining in human NASH...
  11. ncbi request reprint NASH and cryptogenic cirrhosis: a histological analysis
    Stephen H Caldwell
    Division of Gastroenterology and Hepatology, Digestive Health Center, University of Virginia, Charlottesville, Virginia 22908, USA
    Ann Hepatol 8:346-52. 2009
    ....
  12. doi request reprint Cryptogenic cirrhosis: what are we missing?
    Stephen Caldwell
    Digestive Health Center, GI Hepatology Division, University of Virginia Health Science Center, Charlottesville, VA 22908 0708, USA
    Curr Gastroenterol Rep 12:40-8. 2010
    ..In this article, we review these associations as well as a proposed classification system for cryptogenic cirrhosis and other lesser known genetic and syndromic associations that warrant consideration when evaluating these individuals...
  13. doi request reprint The natural history of non-alcoholic fatty liver disease
    Stephen Caldwell
    Division of Gastroenterology and Hepatology, Digestive Health Center of Excellence, University of Virginia Health System, Charlottesville, VA 22908, USA
    Dig Dis 28:162-8. 2010
    ..Meanwhile, the relationship between these comorbidities will increasingly lead to patients with both coronary disease or malignancy and NASH-related cirrhosis presenting clinicians with a very challenging set of problems in coming years...
  14. ncbi request reprint Therapy of NAFLD: insulin sensitizing agents
    Stephen H Caldwell
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    J Clin Gastroenterol 40:S61-6. 2006
    ..Neither agent has been FDA approved for treating NAFLD, but existing studies have provided much hope for incorporating these medications into NAFLD management strategies in selected patients...
  15. ncbi request reprint Mitochondria in nonalcoholic fatty liver disease
    Stephen H Caldwell
    Division of Gastroenterology and Hepatology, University of Virginia Health System, PO Box 800708, Charlottesville, VA 22908, USA
    Clin Liver Dis 8:595-617, x. 2004
    ..The prominent role of mitochondrial dysfunction in NAFL provides a new and exciting paradigm in which to view this disorder, its complications, and potential dietary and pharmacologic intervention...
  16. ncbi request reprint Imaging and clinical characteristics of focal atrophy of segments 2 and 3 in primary sclerosing cholangitis
    S H Caldwell
    The University of Virginia, Department of Internal Medicine, Charlottesville, United States of America
    J Gastroenterol Hepatol 16:220-4. 2001
    ..We examined 44 consecutive PSC patients to determine the incidence and clinical characteristics of this abnormality, and to correlate imaging studies with the gross appearance...
  17. ncbi request reprint Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials
    Stephen H Caldwell
    Divisions of Gastroenterology and Hepatology, The University of Virginia Health Sciences Center, Box 800708, Charlottesville, VA 22908, USA
    Hepatology 39:592-8. 2004
    ..Herein we review the mechanism of action of this agent, report the clinical applications in patients with liver disease, address the limitations and risks associated with the drug, and discuss the issue of its cost-effectiveness...
  18. ncbi request reprint The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease
    Stephen H Caldwell
    The Division of Gastroenterology and Hepatology, Box 800708, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    J Hepatol 40:578-84. 2004
  19. ncbi request reprint Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease
    S H Caldwell
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA
    Hepatology 29:664-9. 1999
    ..Although there is some diversity that indicates more than one cause, our findings suggest that NASH plays an under-recognized role in many patients with cryptogenic cirrhosis, most of whom are older, type 2 diabetic and obese females...
  20. ncbi request reprint Obesity and hepatocellular carcinoma
    Stephen H Caldwell
    Division of Gastroenterology and Hepatology, University of Virginia Health System, P O Box 800708, Charlottesville, Virginia 22908 0708, USA
    Gastroenterology 127:S97-103. 2004
    ....
  21. ncbi request reprint Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy
    Vanessa M Shami
    Division of Gastroenterology and Hepatology, The University of Virginia, Charlottesville, VA 22908, USA
    Liver Transpl 9:138-43. 2003
    ..Our preliminary experience supports the need for further studies to define the optimal dosing, safety, and efficacy of rFVIIa in patients with FHF...
  22. doi request reprint Protective value of TIPS against the development of hydrothorax/ascites and upper gastrointestinal bleeding after balloon-occluded retrograde transvenous obliteration (BRTO)
    Wael Ea Saad
    Division of Vascular Interventional Radiology, Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia, USA
    Am J Gastroenterol 108:1612-9. 2013
    ....
  23. doi request reprint The effect of balloon-occluded transvenous obliteration of gastric varices and gastrorenal shunts on the hepatic synthetic function: a comparison between Child-Pugh and model for end-stage liver disease scores
    Wael E A Saad
    Division of Vascular Interventional Radiology, Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, VA, USA
    Vasc Endovascular Surg 47:281-7. 2013
    ..To evaluate the effect of balloon-occluded transvenous obliteration (BRTO) on the model for end-stage liver disease (MELD) and the Child-Pugh (C-P) score and their individual components...
  24. doi request reprint Ectopic varices: anatomical classification, hemodynamic classification, and hemodynamic-based management
    Wael E A Saad
    Division of Vascular and Interventional Radiology, Department of Radiology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Tech Vasc Interv Radiol 16:158-75. 2013
    ..It is the hope that with better understanding, description, and categorization of ectopic varices comes a more systematic approach to this rare but menacing problem. ..
  25. doi request reprint The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology
    Stephen Caldwell
    Division of Gastroenterology and Hepatology, Digestive Health Center of Excellence, University of Virginia Health System, P O Box 800708, Charlottesville, VA 22908 0708, USA
    J Gastroenterol 44:96-101. 2009
    ..The relative efficacy of these agents will likely depend on the biochemical pathways active in a given hepatocellular malignancy. This, in turn, is likely to be related to the epidemiological associations of HCC...
  26. ncbi request reprint The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis
    Tri H Le
    Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia, USA
    Hepatology 39:1423-9. 2004
    ..In this study, their presence did not seem to correlate with the light microscopic injury pattern represented by ballooned hepatocytes or degree of oxidative stress defined by immunostaining for 4-hydroxynonenal...
  27. doi request reprint Statins in liver disease: a molehill, an iceberg, or neither?
    Curtis K Argo
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA
    Hepatology 48:662-9. 2008
    ..Research using histological endpoints is urgently needed to determine the indications and contraindications of this extraordinary class of agents in patients with chronic liver disease...
  28. doi request reprint Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma
    Alyson McIntosh
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville, Virginia, USA
    Cancer 115:5117-25. 2009
    ..In this study, the authors investigated the feasibility, toxicity, and efficacy associated with intensity-modulated radiation therapy (IMRT) and concurrent, chronomodulated capecitabine in the treatment of unresectable HCC...
  29. doi request reprint Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?
    Curtis K Argo
    Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908 0708, USA
    J Clin Gastroenterol 43:565-8. 2009
    ..A recent clinical study suggests that relapse of NASH pathophysiology is inevitable and that lifelong therapy may be needed to maintain histologic response...
  30. doi request reprint Epidemiology and natural history of non-alcoholic steatohepatitis
    Curtis K Argo
    Division of Gastroenterology and Hepatology, University of Virginia Health System, 1335 Lee Street, MSB 2091, Box 800708, Charlottesville, VA 22908 0708, USA
    Clin Liver Dis 13:511-31. 2009
    ..This article describes the epidemiology and natural history of this disorder. It also describes current diagnostic and treatment methods and describes future implications NAFLD may have...
  31. doi request reprint The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue?
    Neeral L Shah
    Division of Gastroenterology and Hepatology, West Complex Box 800708, Department of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908, USA
    Clin Liver Dis 13:87-93. 2009
    ....
  32. doi request reprint Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
    Curtis K Argo
    Division of Gastroenterology and Hepatology, University of Virginia Health System, JPA and Lee St, MSB 2091, PO Box 800708, Charlottesville, VA, USA
    J Hepatol 51:371-9. 2009
    ....
  33. doi request reprint Regional citrate anticoagulation in critically ill patients with liver and kidney failure
    Rasheed A Balogun
    Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA
    J Nephrol 25:113-9. 2012
    ..The study compares the circuit lifespan and metabolic complications using RCA for CRRT at varying levels of liver dysfunction...
  34. ncbi request reprint Subacute liver failure in obese women
    Stephen H Caldwell
    Department of Internal Medicine, University of Virginia, Charlottesville 22908 0708, USA
    Am J Gastroenterol 97:2058-62. 2002
    ..The patients had findings suggestive of an acute exacerbation of previously unrecognized nonalcoholic steatohepatitis (NASH)...
  35. ncbi request reprint Clear cell hepatocellular carcinoma arising 25 years after the successful treatment of an infantile hepatoblastoma
    Jeffrey Basile
    Department of Medicine, University of Virginia Medical Center, Charlottesville, USA
    Ann Hepatol 9:465-7. 2010
    ..Further knowledge of liver tumorigenesis will help elucidate the complicated genetic, molecular, and environmental factors involved in the development of these two rare hepatic malignancies...
  36. ncbi request reprint Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related?
    Vinay Sundaram
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia 22908 0708, USA
    Dig Dis Sci 51:1203-5. 2006
  37. ncbi request reprint Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism
    Patrick G Northup
    Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia, USA
    Am J Gastroenterol 101:1524-8; quiz 1680. 2006
    ..This study aims to determine the incidence and predictors of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism, in hospitalized patients with cirrhosis...
  38. ncbi request reprint Therapy of NAFLD: antioxidants and cytoprotective agents
    Charissa Y Chang
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    J Clin Gastroenterol 40:S51-60. 2006
    ..Particular promise may exist in the use of these agents in combination therapy with ones that target other aspects in the pathogenesis of NAFLD, such as insulin-sensitizing agents...
  39. ncbi request reprint Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference
    Brent A Neuschwander-Tetri
    Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, MO 63110, USA
    Hepatology 37:1202-19. 2003
    ....
  40. ncbi request reprint Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities
    Kelli A Reardon
    Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908 0383, USA
    Technol Cancer Res Treat 8:71-7. 2009
    ..This study concluded that Yttrium-90 is a low-toxicity, outpatient alternative for individuals with liver cancer and without many options. The maximal value, however, may lie in the treatment of low-risk patients...
  41. ncbi request reprint Is NASH underdiagnosed among African Americans?
    Stephen H Caldwell
    Department of Internal Medicine, University of Virginia, Charlottesville 22908 0708, USA
    Am J Gastroenterol 97:1496-500. 2002
    ..Because obesity and type 2 diabetes are prevalent among African American females by the 5th and 6th decades, one would expect an increased number of African Americans among patients with NASH and cryptogenic cirrhosis...
  42. ncbi request reprint N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis
    Bruce D Greenwald
    Division of Gastroenterology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Am J Gastroenterol 98:1982-8. 2003
    ..We report the initial US experience with cyanoacrylate in this prospective trial and evaluate its safety, efficacy, and relative costs...
  43. ncbi request reprint Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis
    Stephen H Caldwell
    Hepatology 46:285-7. 2007
  44. ncbi request reprint The role of recombinant factor VIIa in liver transplantation
    Robert J Porte
    Liver Transpl 11:872-4. 2005
  45. ncbi request reprint Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet
    Vicência Mara Rodrigues de Lima
    Department of Gastroenterology LIM 07, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
    Liver Int 27:227-34. 2007
    ..The aim of this study was to evaluate the role of the effect of YHK in experimental NASH...
  46. ncbi request reprint Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH?
    Stephen H Caldwell
    Am J Gastroenterol 101:1677-8. 2006
  47. ncbi request reprint The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit
    Stephen H Caldwell
    Pharmacoepidemiol Drug Saf 12:303-6. 2003
  48. ncbi request reprint Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis
    Abdullah M S Al-Osaimi
    Hepatology 41:943. 2005
  49. ncbi request reprint Treatment of bleeding gastric varices
    Patrick G Northup
    J Gastroenterol Hepatol 20:1631-3. 2005

Research Grants1

  1. Omega-3 Fish Oil for Nonalcoholic Steatohepatitis
    Stephen Caldwell; Fiscal Year: 2007
    ....